Q-omics provides the consensus-scored GAPDHP21 profile across patient tissues and cancer cell-line models. GAPDHP21 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, GAPDHP21 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, GAPDHP21 RNA expression shows 15,593 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KIRC, and THYM as cancer lineages where GAPDHP21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP21 survival associations across molecular data types. GAPDHP21 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP21 RNA expression–survival associations across cancer types. High GAPDHP21 expression shows unfavorable associations in STAD, MESO, LUAD, SARC and ACC, but favorable associations in UCS. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .013). Together, the overview and detailed table identify STAD as the clearest survival context for GAPDHP21 RNA expression.
This table summarizes GAPDHP21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP21 shows higher tumor expression in KIRC, COAD, HNSC, LUAD, UCEC and KIRP. The KIRC box plot shows higher GAPDHP21 RNA expression in tumor versus normal tissue (log2 FC = +0.318, t-test p < 0.001).
This table shows molecular features associated with GAPDHP21 in patient tissues and cancer cell lines. In patient samples, GAPDHP21 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
